A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

Launched by BAYER · Apr 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called aflibercept in people with two eye disorders: neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Both conditions can cause blurry vision and are treated with aflibercept, which is injected into the eye to help improve vision. The goal of the study is to gather information about how Japanese patients with these conditions are treated with aflibercept in their regular healthcare settings. Researchers will look at health details when patients first start the treatment and track their progress over a year.

To be eligible for this study, participants need to be prescribed aflibercept 8 mg and must be between the ages of 65 and 74. The study will only collect data from patients already receiving this treatment, so no extra visits or tests are required. This research aims to provide more insights into how aflibercept is used in Japan, which can help improve care for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who are prescribed aflibercept 8 mg during the observable period from the collected data.
• Exclusion Criteria:
• • Patients in the nAMD cohort or nAMD and DME cohort who have the ICD-10 codes for nAMD who are aged \<40 years old.
• • Patients in the DME cohort or others who are aged \<18 years old.
• • Female patients who have any pregnancy-related records.
• • Patients who do not have at least 365 days of continuous enrollment in the database.